Therapeutic options for HIV-associated lymphomas

Bibliography

• Goedert JJ, Cote TR, Virgo P, Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-9
   PubMed Web of Science ®Google Scholar
• Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000;27:442-53
   PubMed Web of Science ®Google Scholar
• IARC monographs on the evaluation of carcinogenic risks to humans. Human immunodeficiency viruses and human T-cell lymphotrophic viruses. Volume 67. International Agency for Research on Cancer/World Health Organization, Lyon; 1996
   Google Scholar
• Chang Y, Cesarman E, Pessin MS, Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9
   PubMed Web of Science ®Google Scholar
• Raphael M, Said J, Borisch B, Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, , editors, World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon; 2008. p. 340-2
   Google Scholar
• Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005;130:662-70
   PubMed Web of Science ®Google Scholar
• Cesarman E, Chang Y, Moore PS, Kaposi's sarcoma-associated herpesvirus-like DNA sequences are present in AIDS-related body cavity-based lymphoma. N Engl J Med 1995;332:1186-91
   PubMed Web of Science ®Google Scholar
• Chadburn A, Hyjek E, Mathew S, KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 2004;28:1401-16
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Vaccher E, Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas. A tissue-based variant of primary effusion lymphoma. J Mol Diagn 2005;7:17-27
   PubMed Web of Science ®Google Scholar
• Delecluse HJ, Anagnostopoulos I, Dallenbach F, Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89:1413-20
   PubMed Web of Science ®Google Scholar
• Carbone A, Gaidano G, Gloghini A, AIDS-related plasmablastic lymphomas of the oral cavity and jaws: a diagnostic dilemma. Ann Otol Rhinol Laryngol 1999;108:95-9
   PubMed Web of Science ®Google Scholar
• Dupin N, Diss TL, Kellam P, HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95:1406-12
   PubMed Web of Science ®Google Scholar
• Carbone A, Cesarman E, Spina M, HIV-associated lymphomas and gamma-herpesviruses. Blood 2009;113:1213-24
   PubMed Web of Science ®Google Scholar
• Cesarman E, Knowles DM. The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Semin Cancer Biol 1999;9:165-74
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol 2008;140:13-24
   PubMed Web of Science ®Google Scholar
• Capello D, Vitolo U, Pasqualucci L, Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000;95:651-9
   PubMed Web of Science ®Google Scholar
• Carbone A, Gaidano G, Gloghini A, Differential expression of BCl-6, CD138/syndecan-1 and EBV-encoded latent membrane protein-1 identifies distinct histogenetic pathways of AIDS-related non-Hodgkin's lymphomas. Blood 1998;91:747-55
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Larocca LM, Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subset of human immunodeficiency virus-related lymphomas. Blood 2001;97:744-51
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Chang CC, Cechova K, BCL-6 protein is expressed in germinal-center B cells. Blood 1995;86:45-53
   PubMed Web of Science ®Google Scholar
• Gaidano G, Carbone A. MUM1. A step ahead toward the understanding of lymphoma histogenesis. Leukemia 2000;14:449-56
   Google Scholar
• Pasqualucci L, Migliazza A, Fracchiolla N, BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci USA 1998;95:11816-21
   PubMed Web of Science ®Google Scholar
• Shen HM, Peters A, Baron B, Mutation of BCL-6 gene in normal B-cells by the process of somatic hypermutation of Ig genes. Science 1998;280:1750-2
   PubMed Web of Science ®Google Scholar
• Vaccher E, Spina M, Talamini R, Improvement of systemic Human Immunodeficiency virus-related non-Hodgkin's lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;37:1556-64
   PubMed Web of Science ®Google Scholar
• Vaccher E, Tirelli U, Spina M, Age and serum lactate dehydrogenase level are independent prognostic factors in HIV-related non-Hodgkin's lymphoma: a single institution study of 96 patients. J Clin Oncol 1996;14:2217-33
   Google Scholar
• Tirelli U, Spina M, Vaccher E, Clinical evaluation of 451 patients with HIV related non-Hodgkin's lymphoma: experience of the Italian Cooperative Group on AIDS and Tumors (GICAT). Leuk Lymphoma 1995;20:91-6
   PubMed Web of Science ®Google Scholar
• Sparano JA. Clinical aspects and management of AIDS-related lymphoma. Eur J Cancer 2001;37:1296-305
   PubMed Web of Science ®Google Scholar
• Spina M, Carbone A, Vaccher E, Outcome in patients with non-Hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004;38:142-4
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Straus DJ, Testa MA, Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1641-8
   PubMed Web of Science ®Google Scholar
• Mounier N, Spina M, Gabarre J, AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006;107:3832-40
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee S, Chen MG, Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004;22:1491-500
   PubMed Web of Science ®Google Scholar
• Little RF, Pittaluga S, Grant N, Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653-9
   PubMed Web of Science ®Google Scholar
• Toffoli G, Corona G, Cattarossi G, Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol 2004;15:1805-9
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Kaplan LD, Rituximab plus concurrent EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin's lymphoma. Blood 2010;115:3008-16
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Costagliola D, Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009;23:2029-37
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91
   PubMed Web of Science ®Google Scholar
• Spina M, Jaeger U, Sparano JA, Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide (R-CDE) in HIV-associated non-Hodgkin's lymphoma: pooled results from three phase II trials. Blood 2005;105:1891-7
   PubMed Web of Science ®Google Scholar
• Spina M, Simonelli C, Vaccher E, Long-term follow-up of rituxiamb plus infusional cyclophosphamide, doxorubicin, and etoposide (CDE) in combination with HAART in HIV-related non-Hodgkin's lymphomas (NHL) [abstract C001]. Proceedings of the 42nd National Conference of the Italian Society of Haematology (SIE), 18 – 21 October 2009, Milan, Italy. Haematologica 2009;94(Suppl 4):7
   Google Scholar
• Boue F, Gabarre J, Gisselbrecht C, Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-8
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Hematol 2008;140:411-19
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Lee JY, Ambinder RF, Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-43
   PubMed Web of Science ®Google Scholar
• Gutierrez M, Chabner BA, Pearson D, Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:3633-42
   PubMed Web of Science ®Google Scholar
• Lai GM, Chen YN, Mickley LA, P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991;49:696-703
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Nathwani BN, AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23:4430-8
   PubMed Web of Science ®Google Scholar
• Spina M, Simonelli C, Talamini R, Tirelli U. Patients with HIV with Burkitt's lymphoma have a worse outcome than those with diffuse large-cell lymphoma also in the highly active antiretroviral therapy era. J Clin Oncol 2005;23:8132-3
   Google Scholar
• Wang ES, Straus DJ, Teruya-Feldstein J, Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196-205
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera JM, Esteve J, Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica 2003;88:445-53
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera JM, Bergua J, High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008;113:117-25
   PubMed Web of Science ®Google Scholar
• Boulanger E, Gerard L, Gabarre J, Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005;23:4372-80
   PubMed Web of Science ®Google Scholar
• Weiss R, Mitrou P, Arasteh K, Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival – results of the German Multicenter Trial. Cancer 2006;106:1560-8
   PubMed Web of Science ®Google Scholar
• Simonelli C, Spina M, Cinelli R, Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003;21:3948-54
   PubMed Web of Science ®Google Scholar
• Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007;12:569-76
   PubMed Web of Science ®Google Scholar
• Spina M, Gaidano G, Carbone A, Highly active antiretroviral therapy in human herpesvirus-8-related body-cavity-based lymphoma. AIDS 1998;12:955-6
   PubMed Web of Science ®Google Scholar
• Won JH, Han SH, Bae SB, Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus. Int J Hematol 2006;83:328-30
   PubMed Web of Science ®Google Scholar
• Boulanger E, Daniel MT, Agbalika F, Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol 2003;73:143-8
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol 2006;17:1849-50
   PubMed Web of Science ®Google Scholar
• Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001;15:280-2
   PubMed Web of Science ®Google Scholar
• Luppi M, Trovato R, Barozzi P, Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005;19:473-6
   PubMed Web of Science ®Google Scholar
• An J, Sun Y, Fisher M, Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004;18:1699-704
   PubMed Web of Science ®Google Scholar
• Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma 2008;8:300-4
   PubMedGoogle Scholar
• Klass CM, Krug LT, Pozharskaya VP, The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005;105:4028-34
   PubMed Web of Science ®Google Scholar
• Riedel DJ, Gonzalez-Cuyar F, Zhao XF, Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis 2008;8:261-7
   PubMed Web of Science ®Google Scholar
• Schichman SA, McClure R, Schaefer RF, Mehta P. HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: a further expansion of the disease spectrum. Am J Hematol 2004;77:291-5
   PubMed Web of Science ®Google Scholar
• Nasta SD, Carrum GM, Shahab I, Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma 2002;43:423-6
   PubMed Web of Science ®Google Scholar
• Lester R, Li C, Phillips P, Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases. Leuk Lymphoma 2004;45:1881-5
   PubMed Web of Science ®Google Scholar
• Armstrong R, Bradrick J, Liu YC. Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report. J Oral Maxillofac Surg 2007;65:1361-4
   PubMed Web of Science ®Google Scholar
• Panos G, Karveli EA, Nikolatou O, Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. Am J Hematol 2007;82:761-5
   Google Scholar
• Spina M, Vaccher E, Juzbasic S, Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin and etoposide as second-line chemotherapy in 40 patients. Cancer 2001;1:200-6
   Google Scholar
• Gabarre J, Marcelin AG, Azar N. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004;89:1100-8
   PubMed Web of Science ®Google Scholar
• Krishnan AY, Molina A, Zaia J, Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005;105:874-8
   PubMed Web of Science ®Google Scholar
• Re A, Cattaneo C, Michieli M, High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003;21:4423-7
   PubMed Web of Science ®Google Scholar
• Díez-Martín JL, Balsalobre P, Re A, Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009;113:6011-14
   PubMed Web of Science ®Google Scholar
• Balsalobre P, Díez-Martín JL, Re A, Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009;27:2192-8
   PubMed Web of Science ®Google Scholar
• Re A, Michieli M, Casari S, High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009;114:1306-13
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111:5486-95
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Fayad L, Delwail V, Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma [abstract 935]. Blood 2009;114:385-6
   Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-100
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Durig J, Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial [abstract 207]. Blood 2009;114:90
   Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22
   PubMed Web of Science ®Google Scholar
• Teicher BA, Ara G, Herbst R, The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45
   PubMed Web of Science ®Google Scholar
• Blum KA, Baiocchi RA, Alinari L, A phase II trial of induction plus maintenance rituximab and bortezomib in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin's lymphoma. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 3053
   Google Scholar
• Moosmann PR, Heizmann M, Kotrubczik N, Weekly treatment with a combination of bendamustine and bortezomib in relapsed or refractory indolent non-Hodgkin's lymphoma: a single-center phase 1/2 study. ASH Annual Meeting Abstracts. Blood 2008;112: abstract 1574
   Google Scholar
• David KA, Smith MR, Lossos IS, A phase II trial of combination bortezomib (Velcade®) and rituximab for untreated ‘high tumor burden’ indolent non-Hodgkin lymphoma (NHL). ASH Annual Meeting Abstracts. Blood 2008;112: abstract 2004
   Google Scholar
• Di Bella N, Taetle R, Kolibaba K, Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood 2010;115:475-80
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-9
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008;26:1544-52
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-7
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:5404-9
   PubMed Web of Science ®Google Scholar
• Tulpule A, Espina BM, Berman N, Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006;7:59-64
   PubMedGoogle Scholar